Brørs O, Jacobsen S
Eur J Clin Pharmacol. 1979 Sep;16(2):125-31. doi: 10.1007/BF00563119.
The pharmacokinetics of hydroflumethiazide (HFT) were investigated after intravenous and oral administration to healthy subjects. After intravenous infusion, HFT behaved according to a three-compartment model. Two distribution phases were observed, with mean half-lives of 0.26 and 0.85 h, reflecting distribution to red blood cells and tissues. Mean biological half-life (t 1/2 beta) after infusion was 5.2 h. Renal blood and plasma clearance of HFT, as well as the ratio renal blood clearance/renal plasma clearance of HFT, were lower after infusion than during the infusion, due to the distribution characteristics of HFT. After a single oral dose of 2 micronmol/kg, t 1/2 beta was significantly shorter in all subjects than after a single oral dose of 6 micronmol/kg, with mean t 1/2 beta of 8.7 and 17.9 h, respectively. Due to lack of a sufficiently sensitive method for determination of HFT in plasma, it could not be established whether the observed dose-dependent difference in biological half-life of HFT was caused by variation in renal clearance and/or the volume of distribution.
在健康受试者静脉注射和口服氢氟噻嗪(HFT)后,对其药代动力学进行了研究。静脉输注后,HFT的行为符合三室模型。观察到两个分布阶段,平均半衰期分别为0.26小时和0.85小时,反映了向红细胞和组织的分布。输注后的平均生物半衰期(t 1/2β)为5.2小时。由于HFT的分布特性,输注后HFT的肾血清除率和血浆清除率以及HFT的肾血清除率/肾血浆清除率比值均低于输注期间。单次口服剂量2微摩尔/千克后,所有受试者的t 1/2β均显著短于单次口服剂量6微摩尔/千克后,平均t 1/2β分别为8.7小时和17.9小时。由于缺乏足够灵敏的血浆HFT测定方法,无法确定观察到的HFT生物半衰期的剂量依赖性差异是由肾清除率变化和/或分布容积变化引起的。